Updates
** Divi's Laboratories DIVI.NS close up 4.8% at 6,580 rupees after drugmaker posts 23% jump in Q4 profit
** Stock top of Nifty pharma index .NIPHARM, which is up 0.5%
** At least four analysts raise PT on DIVI, lifting the median PT to 5,980 rupees, avg rating is "hold" -LSEG data
** Jefferies ("hold") says Divi's will be a key beneficiary of diversification out of China but sees some near-term earnings pain due to competition as drugmakers' patents expire
** DIVI's F12M PE is 63, highest on pharma index
** Nuvama ("buy") says premium valuation will sustain as Divi's custom synthesis business scales up with new products from large clients
** Stock up ~8% YTD, most on pharma index, which is down 7%
(Reporting by Nandan Mandayam and Hritam Mukherjee in Bengaluru)
((Hritam.Mukherjee@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.